PTAB rejects Sanofi and Regeneron's IPR request

On Oct. 4, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected a request from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) for an inter partes review of a patent owned by Immunex Corp., which Amgen Inc. (NASDAQ:AMGN) acquired in 2002. U.S. Patent No. 8,679,487 covers delivering an IL-4 antagonist to treat conditions induced by IL-4...